BioSpace News Archive

OrthoPediatrics Corp., a company focused exclusively on advancing the field of pediatric orthopedics, provided a business update on the proactive steps it is taking in response to the global COVID-19 pandemic.

Announces publication of accompanying JAMA editorial highlighting important secondary endpoints including congestive heart failure A pabetalone development program moving toward next study to enable a New Drug Application filing CALGARY, Alberta, March 30, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) announced today the recent publication of an article titled: “ Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovas

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that expanded access treatment with the INOpulse® inhaled nitric oxide system (iNO) was initiated for the first time in a patient with a diagnosis of the novel coronavirus disease (COVID-19) at the University of Miami School of Medicine. The treatment follows the recent decision by

InnerScope Hearing Technologies signs an Agreement with Pursuant Health Inc. to launch its Hearing Loss Information Center to all 4,618 of Pursuant Health’s Wellness Screening Kiosks inside all Walmart and Walmart Neighborhood Market locations nationwide by June 2020.

Crucial life-saving initiative led by Dr. Steven Quay for clinical trials on the safety and efficacy of a combination of FDA-approved drugs (nebulized H eparin-N-acetylcysteine in C O VID-19 P atients by E valuation of pulmonary function ( HOPE ))

Immunovia invites you to a teleconference for all stakeholders and media on Wednesday, April 1, 2020 at 16:30 CET.

The device is designed to restore vision to persons blinded by age-related macular degeneration and retinitis pigmentosa

Agilent Technologies Inc. (NYSE: A) today introduced the Agilent K6460S Clinical Edition TQ LC/MS system, designed to improve in vitro diagnostic workflows in clinical labs.

I-Mab (the “Company”) (Nasdaq: IMAB), today announced that it has submitted an Investigational New Drug (IND) application to South Korea’s Ministry of Food and Drug Safety (MFDS), to evaluate the safety and efficacy of TJM2 in treating cytokine storm (CS) in severe and critically ill patients caused by the coronavirus disease (COVID-19).

MedSign International Corporation, a leading-edge Telehealth company, announces the nationwide launch of Qortex™; the first and only home TV-based Telehealth solution that enables doctors, hospitals, nurses, and home care agencies to deliver virtual medical services to patients confined to their homes, especially during this COVID-19 pandemic